Phase 2 Leronlimab, a CCR5-directed mAb in relapsed microsatellite stable colorectal cancer.

This open-label, randomized, multi-center study evaluates two Leronlimab doses combined with trifluridine-tipiracil plus bevacizumab in patients with CCR5-positive metastatic colorectal cancer who progressed on prior treatment. Conducted at sites including San Francisco by CytoDyn, Inc., it aims to assess safety, tolerability, and efficacy outcomes.